Currently, CAR-T therapies have been shown to be effective for certain blood cancers, including lymphomas, leukaemia, and multiple myeloma but the applications ... the field for her 25th game in ...
News Medical on MSN1d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...
In June, GSK released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, ...
GlobalData on MSN22h
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback